|
Years of age, median (range; p10; p90): 56 (18–72; 35; 67)
|
|
18–45
|
105
|
24
| |
0.28
| |
0.29
|
|
46–55
|
98
|
23
| | | | |
|
56–65
|
165
|
38
| | | | |
|
66–72
|
65
|
15
| | | | |
|
Female sex
|
151
|
35
| |
0.39
| |
0.26
|
|
ASCT year
|
|
1994–1999
|
42
|
10
| |
0.43
| |
0.25
|
|
2000–2009
|
161
|
37
| | | | |
|
2010–2016
|
230
|
53
| | | | |
|
Indication for ASCT
|
|
Planned upfront
|
155
|
36
| |
0.054
| |
0.053
|
|
Relapsed/refractory
|
278
|
64
| | | | |
|
Years since lymphoma diagnosis, median (range): 1.2 (0.2–22.6)
| | | |
0.45
| |
0.40
|
|
Number of prior lines of therapy
|
|
1
|
161
|
40
| |
0.16
| |
0.20
|
|
2
|
201
|
50
| | | | |
|
≥ 3
|
44
|
11
| | | | |
|
Days between date of last chemotherapy and date of ASCT, median (range; p10; p90): 35 (20–415; 27; 53)
|
|
< 28
|
54
|
14
| |
0.79
| |
0.48
|
|
28–34
|
135
|
34
| | | | |
|
35–41
|
113
|
28
| | | | |
|
42–55
|
63
|
16
| | | | |
|
≥ 56
|
33
|
8
| | | | |
|
Prior rituximab
|
263
|
61
| |
0.069
| |
0.12
|
|
Prior fludarabine
|
26
|
6
| |
0.91
| |
0.72
|
|
ASCT in poor remission
|
70
|
16
| |
0.32
| |
0.90
|
|
Harvested CD34+ cells/kg, median (range; p10; p90): 6.2 (1.0–48.0; 3.4; 13.7)
|
|
1.0–3.9 million
|
59
|
14
|
2.0 (0.7–6.2)
|
0.040
|
3.4 (1.0–11.4)
|
0.040
|
|
4.0–4.9 million
|
50
|
12
|
4.2 (1.6–11.2)
| |
5.2 (1.6–16.9)
| |
|
5.0–9.9 million
|
228
|
54
|
1
| |
1
| |
|
10.0–48.0 million
|
82
|
20
|
1.4 (0.5–4.3)
| |
1.9 (0.5–6.9)
| |
|
< 5 vs ≥ 5 million
| | |
3.1 (1.5–6.5)
|
0.003
|
4.0 (1.7–9.4)
|
0.001
|
|
Stem cell source
| | | | | | |
|
Peripheral blood
|
424
|
98
|
1
|
0.008
|
1
|
0.002
|
|
Bone marrow
|
9
|
2
|
7.1 (1.7–29.8)
| |
9.4 (2.2–40.3)
| |
|
Leukocytes per nL, median (range; p10, p90): 4.1 (1.0–25.9; 2.2; 7.2)
|
|
Normal or high (≥ 3.5)
|
271
|
65
| |
0.062
| |
0.059
|
|
Neutrophils per nL, median (range; p10; p90): 2.4 (< 0.2–45.0; 1.0; 5.1)
|
|
Normal or high (≥ 1.5)
|
246
|
76
| |
0.13
| |
0.26
|
|
Lymphocytes per nL, median (range; p10; p90): 0.8 (0.3–8.3; 0.4; 1.9)
|
|
Normal or high (≥ 1.0)
|
65
|
37
| |
0.65
| |
0.40
|
|
Platelets per nL, median (range; p10; p90): 199 (7–1395; 105; 363)
|
|
Low (< 150)
|
114
|
27
|
3.2 (1.5–6.6)
|
0.002
|
4.9 (2.1–11.7)
|
0.0003
|
|
Haemoglobin in g/L, median (range; p10; p90): 105 (75–150; 91; 123)
|
|
Low (< 120)
|
364
|
87
| |
0.25
| |
0.45
|
|
Creatinine in multiples of UNL, median (range; p10; p90): 0.74 (0.29–1.90; 0.58; 1.02)
|
|
Elevated (≥ UNL)
|
50
|
12
|
2.8 (1.2–6.8)
|
0.018
|
4.1 (1.6–10.1)
|
0.002
|
|
Albumin in g/L, median (range; p10; p90): 37 (14–44; 32; 41)
|
|
Low (< 36)
|
102
|
26
|
2.6 (1.2–5.7)
|
0.016
|
3.2 (1.3–7.9)
|
0.013
|
|
C-reactive protein in mg/L, median (range; p10; p90): 2 (0–169; 0; 20)
|
|
< 3
|
160
|
50
|
1
|
0.0006
|
1
|
0.0013
|
|
3–9
|
83
|
26
|
5.6 (1.4–21.6)
| |
6.3 (1.2–31.9)
| |
|
≥ 10
|
75
|
24
|
9.0 (2.4–33.3)
| |
11.0 (2.3–52.5)
| |
|
Conditioning
| | | | | | |
|
BEAM
|
403
|
93
| |
0.61
| |
0.80
|
|
BEAC
|
22
|
5
| | | | |
|
BCNU-thiotepa
|
7
|
2
| | | | |
|
Cy-TBI
|
1
|
0
| | | | |
|
Given dose of CD34+ cells/kg, median (range; p10; p90): 6.0 (1.0–48.0; 3.4; 11.4)
|
|
1.0–3.9 million
|
61
|
15
| |
0.087
| |
0.071
|
|
4.0–4.9 million
|
58
|
14
| | | | |
|
5.0–9.9 million
|
233
|
56
| | | | |
|
10.0–48.0 million
|
66
|
16
| | | | |
|
Tandem-treatment after ASCT
|
45
|
10
| |
1.0
| |
1.0
|
|
Local irradiation
|
22
|
5
| | | | |
|
Splenectomy
|
2
|
0
| | | | |
|
Temozolomide maintenance
|
18
|
4
| | | | |
|
Allogeneic SCT
|
3
|
1
| | | | |
